Clinical Trial Update: Phase 1 of EC1169 In Patients With Recurrent MCRPC [Phase 1]

View source ↗

Summary

Phase 1 results update for EC1169 in patients with recurrent metastatic castration-resistant prostate cancer (MCRPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• EC1169

Snippet

Sponsor: Endocyte | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED